Live Bending Spoons Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about

iBio, Inc.

IBIO

Latest SEC Filings from iBio, Inc.

  1. 1
    1

    iBio Reports $33M Net Loss and Progress in Clinical Trials for IBIO-600

    via official filing (AI summary) about 2 months ago 0 comments
  2. 2
    1

    iBio Reports Increased Operating Expenses and Continued Net Loss for Three and Nine Months Ended March 31, 2026

    via official filing (AI summary) 5 months ago 0 comments
  3. 3
    1

    iBio Reports No Revenue and Increased Losses in Latest Financial Filing

    via official filing (AI summary) 8 months ago 0 comments
  4. 4
    1

    iBio Reports $100,000 Revenue and $5.7 Million Net Loss for Q3 2025

    via official filing (AI summary) 11 months ago 0 comments
  5. 5
    1

    iBio Reports $18.4 Million Net Loss for Fiscal Year Ending June 30, 2025

    via official filing (AI summary) about 1 year ago 0 comments
  6. 6
    1

    iBio Reports $4.9 Million Net Loss and Revenue Growth in Latest Financial Results

    via official filing (AI summary) over 1 year ago 0 comments
  7. 7
    1

    iBio Reports $200,000 Revenue in Q2 FY2025, Continues to Face Net Losses

    via official filing (AI summary) over 1 year ago 0 comments
  8. 8
    1

    iBio Reports Significant Financial Changes, Shifts Focus to Preclinical Pipeline Development

    via official filing (AI summary) almost 2 years ago 0 comments